Trial · NCT04692285
Electrophysiological and Neuroimaging Correlates of the Effect of Zolpidem in Patients With Focal Dystonia
NCT04692285, Phase 1, Completed, University Medical Centre Ljubljana
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Electrophysiological and Neuroimaging Correlates of the Effect of Zolpidem in Patients With Focal Dystonia. Trials, record NCT04692285. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04692285
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Electrophysiological and Neuroimaging Correlates of the Effect of Zolpidem in Patients With Focal Dystonia
- NCT number
- NCT04692285
- Status
- Completed
- Phases
- Phase 1
- Enrollment
- 24 participants, actual
- Lead sponsor
- University Medical Centre Ljubljana
- Conditions
- Focal Dystonia
- Interventions
- Zolpidem, Placebo
- First posted
- 2020-12-31
- Last updated
- 2023-12-04
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in the transcranial magnetic stimulation measures between zolpidem 5 mg and placebo | 30 minutes after the intervention | Transcranial magnetic stimulation measures (resting and active cortical motor threshold, resting and active input-output curve, short intracortical inhibition, long intracortical inhibition, intracortical facilitation) after zolpidem 5 mg and placebo will be compared. |
| Primary | Change in brain metabolism detected on FDG-PET CT brain imaging between zolpidem 5 mg and placebo | 30 minutes after the intervention | FDG-PET CT brain imaging |
| Secondary | Change in The Burke-Fahn-Marsden Dystonia Rating Scale (BFMS) between zolpidem 5 mg and placebo | 30 minutes after the intervention | Dystonia can be objectively assessed using the BFMS. The BFMS is subdivided into a movement scale and a disability scale. Only the movement scale will be used. The minimum total score is 0, the maximal total score is 120. Patients who are more affected with dystonia get higher scores. |
| Other | Change in The Writer's Cramp Rating Scale (WCRS) between zolpidem 5 mg and placebo | 30 minutes after the intervention | The writer's cramp dystonia can be objectively assessed using WCRS. The minimum score on WCRS is 0 and the maximum score is 30. The WCRS consists of two subscores, the writing movement score with the minimum score 0 and the maximum score 28 and the writing speed score with the minimum score 0 and the maximum score 2. The higher the score, the more is a patient affected with the writer's cramp dystonia. |
| Other | Change in the Visual Analog Score between zolpidem 5 mg and placebo | 30 minutes after the intervention | To subjectively assess dystonia, the Visual Analog Scale will be used. The minimum score on the scale will be 0 and the maximum score will be 10. A higher score will mean a greater impairment due to the presence of dystonia. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers4
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04692285
GET https://conductscience.org/api/trials/v1/NCT04692285/registered